Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human RRM2 Antibodies:
anti-Mouse (Murine) RRM2 Antibodies:
anti-Rat (Rattus) RRM2 Antibodies:
Go to our pre-filtered search.
Human Monoclonal RRM2 Primary Antibody for IF, IHC (p) - ABIN562744
Tang, Deng, Wang, Dai, Wang, Jiang, Li, Li, Sheng, Wu, Li, Zeng et al.: Quantitative phosphoproteome profiling of Wnt3a-mediated signaling network: indicating the involvement of ribonucleoside-diphosphate reductase M2 subunit phosphorylation at residue serine 20 in ... in Molecular & cellular proteomics : MCP 2007
Show all 5 Pubmed References
Human Monoclonal RRM2 Primary Antibody for IF, IHC (p) - ABIN2476387
Neinstein: Abdominal and flank pain as presenting symptoms of schwannoma. in Journal of adolescent health care : official publication of the Society for Adolescent Medicine 1989
Show all 2 Pubmed References
Cow (Bovine) Polyclonal RRM2 Primary Antibody for WB - ABIN2782440
Souglakos, Boukovinas, Taron, Mendez, Mavroudis, Tripaki, Hatzidaki, Koutsopoulos, Stathopoulos, Georgoulias, Rosell: Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. in British journal of cancer 2008
Show all 2 Pubmed References
Human Polyclonal RRM2 Primary Antibody for IF, WB - ABIN2452118
Takada, Shibata, Hiraoka, Masuda: Identification of ribonucleotide reductase protein R1 as an activator of microtubule nucleation in Xenopus egg mitotic extracts. in Molecular biology of the cell 2000
Data show that inhibition of sphingosine kinase-2 (show SPHK2 Antibodies) by ABC294640 is synergistically cytotoxic with gemcitabine toward three pancreatic cancer cell lines, resulting in decreased expression of both ribonucleotide reductase regulatory subunit M2 (RRM2) and c-MYC (show MYC Antibodies) protein (Myc (show MYC Antibodies)) in all three cell lines.
Based on the results of clinical trials, we conclude that Ribonucleotide reductase (RR) enzymes (RR1 (show RRM1 Antibodies) and RR2)inhibitors are viable treatment options, either as a monotherapy or as a combination in cancer chemotherapy. With the recent advances made in cancer biology, further development of RR inhibitors with improved efficacy and reduced toxicity is possible for treatment of variety of cancers.
Here we designed UC-rich and CU-rich 10-nt sequences for engagement of both RRM2 and RRM3 and demonstrated that the TIA-1 (show TIA1 Antibodies) RRM23 construct preferentially binds the UC-rich RNA ligand. Together our data support a specific mode of TIA-1 (show TIA1 Antibodies) RRM23 interaction with target oligonucleotides consistent with the role of TIA-1 (show TIA1 Antibodies) in binding RNA to regulate gene expression
These data suggest that VASH2 (show VASH2 Antibodies) reduces the chemosensitivity to gemcitabine in pancreatic cancer cells via JUN (show JUN Antibodies)-dependent transactivation of RRM2.
HPV31 regulates RRM2 levels through expression of E7 and activation of the ATR (show ANTXR1 Antibodies)-Chk1 (show CHEK1 Antibodies)-E2F1 (show E2F1 Antibodies) DNA damage response, which is essential to combat replication stress upon entry into S-phase.
To the best of our knowledge, this is the first study that investigated the relationship of RRM1 (show RRM1 Antibodies) and RRM2 gene polymorphisms and Coronary artery disease (CAD (show CAD Antibodies)).
The SCYL1- BP1 (show GORAB Antibodies) affects the cell cycle through increasing steady state levels of Cyclin F (show CCNF Antibodies) and RRM2 proteins, thus constituting a dual regulatory circuit.
A significant association has been found between RRM2 rs6759180 (located in the 5'UTR (show UTS2R Antibodies), 10126436G>A) and the risk for developing non-small cell lung cancer.
Data show that ribonucleotide reductase M2 (RRM2) is associated with increased nuclear factor kappa B (NF-kappaB (show NFKB1 Antibodies)) activity.
our findings establish a signaling role for RRM2 in gastric cancer cells and identify that the RRM2/AKT (show AKT1 Antibodies)/NF-kappaB (show NFKB1 Antibodies) signaling pathway is essential for tumor invasiveness in gastric cancer cells
This work reveals that binding of RRM1 (show RRM1 Antibodies) to RRM2 is essential for mammalian cells and provides the first loss-of-function model of the ribonucleotide reductase complex for genetic studies.
mice carrying extra alleles of the RNR (show REN1 Antibodies) regulatory subunit RRM2 (Rrm2(TG)) present supraphysiological RNR (show REN1 Antibodies) activity and reduced chromosomal breakage at fragile sites
analysis of transgenic overexpression of ribonucleotide reductase Rrm1 (show RRM1 Antibodies) and Rrm2 improves cardiac performance
Cinobufotalin significantly inhibits the growth of the xenografts of endometrial carcinoma Ishikawa in nude mice by inhibiting RRM2 expression.
Data suggest that RRM2 may be an important effector of progesterone signaling to induce cell proliferation and decidualization in uterus.
illegitimate recombination initiated by c-Myc (show MYC Antibodies)
Adrenergic stimulation of brown adipocytes elevates ribonucleotide reductase subunit R2 in the proliferative stage of adipocyte development; mediating pathways include cAMP/PKA cascades, Src (show SRC Antibodies) and Erk (show EPHB2 Antibodies) Map Kinases.
S Phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F (show E2F1 Antibodies)-binding site and an upstream promoter activating region
Chk1 is required for DNA replication at least through regulating RNR2 gene transcription.
results indicate that the affinity of the RNR (show REN1 Antibodies) R2 proteins for binding metals is determined by the nature of one specific residue in the vicinity of the dimetal site, namely the one that carries the tyrosyl radical in class Ia and Ib R2 proteins
This gene encodes one of two non-identical subunits for ribonucleotide reductase. This reductase catalyzes the formation of deoxyribonucleotides from ribonucleotides. Synthesis of the encoded protein (M2) is regulated in a cell-cycle dependent fashion. Transcription from this gene can initiate from alternative promoters, which results in two isoforms that differ in the lengths of their N-termini. Related pseudogenes have been identified on chromosomes 1 and X.
ribonucleoside-diphosphate reductase subunit M2
, ribonucleotide reductase M2 polypeptide
, ribonucleotide reductase small chain
, ribonucleotide reductase small subunit
, ribonucleoside-diphosphate reductase M2 chain
, Ribonucleotide reductase 2
, reductase M2 polypeptide variant 1
, reductase M2 polypeptide variant 2
, reductase M2 polypeptide variant 3a
, reductase M2 polypeptide variant 3b
, reductase M2 polypeptide variant 3c
, reductase M2 polypeptide variant 3d
, ribonucleotide reductase protein r2 class I